4//SEC Filing
Litvack Frank 4
Accession 0001415889-23-012326
CIK 0001133869other
Filed
Aug 15, 8:00 PM ET
Accepted
Aug 16, 5:00 PM ET
Size
9.6 KB
Accession
0001415889-23-012326
Insider Transaction Report
Form 4
Litvack Frank
Director
Transactions
- Tax Payment
Common Stock
2023-08-14$6.61/sh−4,364$28,846→ 133,269 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-08-14−20,748→ 0 totalExercise: $1.39Exp: 2023-08-21→ Common Stock (20,748 underlying) - Exercise/Conversion
Common Stock
2023-08-14$1.39/sh+20,748$28,840→ 137,633 total
Footnotes (4)
- [F1]This amount has been adjusted to correct an administrative error in the Form 4 filed by the reporting person on February 23, 2023, which inadvertently overstated the amount of common stock beneficially owned by 20,391 shares.
- [F2]Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on August 14, 2023 of $6.61. The options would otherwise expire on August 21, 2023, pursuant to their terms.
- [F3]This option was granted on August 21, 2013 and was previously reported as covering 207,485 shares at an exercise price of $0.30 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
- [F4]The stock option award is fully vested and exercisable.
Documents
Issuer
CAPRICOR THERAPEUTICS, INC.
CIK 0001133869
Entity typeother
Related Parties
1- filerCIK 0001310715
Filing Metadata
- Form type
- 4
- Filed
- Aug 15, 8:00 PM ET
- Accepted
- Aug 16, 5:00 PM ET
- Size
- 9.6 KB